According to a systematic review and meta-analysis, serum IGF1 levels in MASLD patients were significantly lower than those in the healthy control group, with this difference being particularly pronounced in non-alcoholic steatohepatitis (NASH) patients.43 Here, IGF1 is linked to metabolic dysfunction-associated steatotic liver disease.